Rivaroxaban (RXB), an oral direct factor Xa inhibitor, presents innovative therapeutic profile.
However, RXB has shown adverse effects, mainly due to pharmacokinetic limitations …

The aim of this study was to improve rivaroxaban water-solubility by cocrystal preparation
and to understand this process. The screening with water-soluble coformers was performed …

Purpose Because some patients have difficulty swallowing a whole tablet, we investigated
the relative bioavailability of a crushed 20 mg rivaroxaban tablet and of 2 alternative crushed …

BCS class II drugs exhibit low aqueous solubility and high permeability. Such drugs often
have an incomplete or erratic absorption profile. This study aimed to predict the effects of β …

Rivaroxaban (RXB), a novel oral anticoagulant that directly inhibits factor Xa, is a poorly
soluble drug belonging to Biopharmaceutics Classification System (BCS) class II. In this …

To tailor the solid state properties of rivaroxaban (RXB), microparticles were prepared using
an anti-solvent precipitation technique. A mixture of hydroxypropyl methylcellulose (HPMC) …

Purpose This study aimed to ensure the convenience of administration and reproducibility of
efficacy, regardless of the meal, by improving the solubility of rivaroxaban (RIV). Methods …

Rivaroxaban (RIV) is a direct Factor Xa inhibitor anticoagulant, but the oral bioavailability of
RIV is estimated to be only 60% due to its poor solubility. The aim of the present study was to …

The most common and preferable route of drug administration is through the oral route.
Novel oral drug delivery systems aim to enhance safety and efficacy of drug molecule by …